Martin Huber

Martin Huber

Direktör/Styrelseledamot på SYNDAX PHARMACEUTICALS, INC.

Förmögenhet: 1 M $ per 2026-05-31

66 år
Health Technology
Consumer Services

Profil

Martin H.
Huber
is currently an Independent Director at Syndax Pharmaceuticals, Inc. since 2021 and an Independent Director at Actuate Therapeutics, Inc. starting in 2026.
Former positions include President, Chief Executive Officer & Director at Mersana Therapeutics, Inc. from 2023 to 2026; President, Head-Research & Development at Xilio Therapeutics, Inc. from 2022 to 2023; Senior Vice President-Clinical at GSK Plc from 2019 to 2020; Chief Medical Officer & Senior Vice President at Tesaro, Inc. from 2015 to 2019; Vice President-Oncology Clinical Research at Merck Research Laboratories Massachusetts LLC from 2012 to 2015; Vice President-Global Pharmacovigilance at Schering-Plough Corp.; Assistant Professor at The University of Texas M.D.
Anderson Cancer Center.
Education includes undergraduate studies at Texas Lutheran University and a doctorate from Baylor College of Medicine.

Kända innehav i offentliga företag

FöretagDatumAntal aktierVärderingVärderingsdatum
2026-03-30 74 000 ( 0,08 % ) 1 M $ 2026-05-31

Aktiva positioner av Martin Huber

FöretagPositionStart
SYNDAX PHARMACEUTICALS, INC. Direktör/Styrelseledamot 2021-09-15
ACTUATE THERAPEUTICS, INC. Direktör/Styrelseledamot 2026-05-01

Tidigare kända positioner av Martin Huber

FöretagPositionSlut
MERSANA THERAPEUTICS Verkställande Direktör 2026-01-06
XILIO THERAPEUTICS, INC. President 2023-09-08
GSK PLC Teknisk/Vetenskaplig/F&U Direktör 2020-04-01
TESARO INC Teknisk/Vetenskaplig/F&U Direktör 2019-01-22
Företagsledare/Principal 2015-01-01
Se detaljerna i Martin Hubers erfarenhet

Martin Hubers utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

40

Första gradens relationer

11

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

  1. Börsen
  2. Insiders
  3. Martin Huber